DanCann Pharma A/S delivers annual shareholder letter and investor update
COPENHAGEN, Denmark, 20 December 2023 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby issues an annual shareholder letter and update from its CEO, Jeppe Krog Rasmussen, to its investors as the year comes to a close.Table of content: · Summary and conclusion of 2023 · Upcoming value drivers · 2025 guidance · Delivering on the future business · Submission of new dossier · MYCB1 partnership to accelerate growth · Capital requirements for implementing the adjusted strategy · Biotech Pharm1 (BP1) –